Actavis Approved for Generic Intuniv Tablets

Actavis announced that the FDA has granted tentative approval for Guanfacine Extended-release Tablets, the generic of Shire‘s Intuniv tablets.

Intuniv is a central α_2A-agonist indicated in attention deficit hyperactivity disorder (ADHD), as monotherapy or as an adjunct to stimulant medications. Intuniv is not a controlled substance and has no known potential for abuse or dependence. Its mechanism of action in ADHD is unknown.

Guanfacine Extended-release Tablets will be available from Actavis in 1mg, 2mg, 3mg and 4mg in the future.

For more information call (973) 993-4500 or visit www.actavis.us.